Claims
- 1. A composition of matter, comprising a recombinant fusion toxin comprising:
- a toxin fused to a targeting moiety which binds to a receptor overexpressed by tumor cells, wherein said toxin-targeting fusion moiety is labeled with a radionuclide.
- 2. The composition of claim 1, wherein said toxin is selected from the group consisting of diphtheria toxin, ricin, gelonin and pseudomonas exotoxin.
- 3. The composition of claim 1, wherein said radionuclide is selected from the group consisting of .sup.90 Y, .sup.186 Re, .sup.188 Re, .sup.64 Cu, .sup.67 Cu, .sup.212 Pb, .sup.212 Bi, .sup.123 I, .sup.211 At, .sup.213 Bi and .sup.131 I.
- 4. The composition of claim 1, wherein said targeting moiety that binds to receptors overexpressed by tumor cells is selected from the group consisting of the interleukin-4, interleukin-2, epidermal growth factor and the granulocyte macrophage colony stimulating factor.
- 5. The composition of claim 1, wherein said tumor cell is selected from the group consisting of an acute myeloid leukemia cell, a melanoma cell, a small-cell carcinoma of the lung cell, a breast cancer cell, a renal carcinoma cell, a glioma cell, a gastric carcinoma cell, an ovarian carcinoma cell, a prostate cancer cell and a colon cancer cell.
- 6. The composition of claim 1, wherein said recombinant fusion toxin is DT.sub.390 -mGM-CSF.
- 7. The composition of claim 1, wherein said recombinant fusion toxin is DT.sub.390 -mIL-4.
- 8. A pharmaceutical composition, comprising the composition of claim 1.
- 9. A method of killing a tumor cell, comprising the step of contacting said cell with the composition of claim 1.
- 10. The method of claim 9, wherein said cell is selected from the group consisting of an acute myeloid leukemia cell, a melanoma cell, a small-cell carcinoma of the lung cell, a breast cancer cell, a renal carcinoma cell, a glioma, a gastric carcinoma cell, an ovarian carcinoma cell, and a colon cancer cell.
- 11. A method of treating a tumor cell in an individual in need of said treatment, comprising the step of administering to said patient an effective dose of the composition of claim 8.
CROSS REFERENCE TO RELATED APPLICATION
The present application claims priority to provisional application U.S. Ser. No. 60/016,982, filed May 16, 1996, now abandoned.
US Referenced Citations (4)